Back to Search Start Over

Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact.

Authors :
Galar A
Valerio M
Muñoz P
Alcalá L
García-González X
Burillo A
Sanjurjo M
Grau S
Bouza E
Source :
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2017 Sep 22; Vol. 61 (10). Date of Electronic Publication: 2017 Sep 22 (Print Publication: 2017).
Publication Year :
2017

Abstract

Linezolid serum trough ( C <subscript>min</subscript> ) and peak ( C <subscript>max</subscript> ) levels were determined prospectively in 90 patients. Adequate exposure was defined as a C <subscript>min</subscript> of 2 to 8 mg/liter. Therapy was empirical (73.3%) or targeted (26.7%). Wide interindividual variability in linezolid C <subscript>min</subscript> levels was recorded (0.1 to 25.2 μg/ml). Overall, 65.5% of the patients had out-of-range, 41.1% had subtherapeutic, and 24.4% had supratherapeutic trough levels. We did not find a correlation between abnormal levels and adverse events, in-hospital mortality, or overall poor outcome.<br /> (Copyright © 2017 American Society for Microbiology.)

Details

Language :
English
ISSN :
1098-6596
Volume :
61
Issue :
10
Database :
MEDLINE
Journal :
Antimicrobial agents and chemotherapy
Publication Type :
Academic Journal
Accession number :
28739788
Full Text :
https://doi.org/10.1128/AAC.00687-17